Tevogen Bio Stock Price, News & Analysis

Tevogen (Nasdaq: TVGN) Founder and CEO Dr. Ryan Saadi donated 50,000 shares of his personal Tevogen common stock to the Mt. Bethel Fire Company to support emergency readiness in Warren Township on December 19, 2025. The contributed shares are intended to enhance safety, equipment and response capabilities.

The donation was executed under SEC Rule 144, and Dr. Saadi will not receive proceeds from any disposal of the securities. The announcement also states an estimated $10 billion asset valuation for the company and a secured cash runway through commercialization.

Tevogen (Nasdaq: TVGN) announced that Founder and CEO Dr. Ryan Saadi donated 230,000 personal shares of common stock to the Warren Township Honorary Policemen’s Benevolent Association (P.B.A.) Local 235 on Dec. 11, 2025. The nonprofit supports local schools, D.A.R.E., Explorer programs, families of fallen/injured officers, and community events. The donation will fund equipment to enhance officer and resident safety. The transfer was made in accordance with SEC Rule 144 and Dr. Saadi will not receive proceeds from the disposal of the securities.

Tevogen (Nasdaq: TVGN) honored board member Curtis Patton, PhD, with a joint portrait at Yale School of Medicine recognizing his decades-long contributions to medical education, mentorship, and public health.

The portrait by Mario Moore will be unveiled on December 11, 2025 at 4 p.m. at the Harvey Cushing/John Hay Whitney Medical Library. Tevogen highlighted Dr. Patton's influence on the company as it advances the ExacTcell™ T cell platform, scales Tevogen.AI predictive technologies, and pursues growth with revenue forecasts exceeding $1 billion.

Tevogen (Nasdaq: TVGN) was named to the 2025 New Jersey Power List by NJBIZ for influence on New Jersey's economic and innovation landscape.

NJBIZ highlighted Tevogen's ExacTcell platform, advancing pipelines in infectious disease, oncology, and neurology, and its internally developed PredicTcell AI for target prediction. The recognition referenced an anticipated ~$1 billion in first-year specialty-care revenue and a cumulative five-year forecast of $18–22 billion. Tevogen also noted expansion including a 17,428-square-foot manufacturing facility and a new headquarters that more than doubles its prior footprint, centralizing R&D, regulatory, and Tevogen.AI operations.

Tevogen (Nasdaq: TVGN) filed its Form 10-Q for the quarter ended September 30, 2025, reporting continued capital-efficient execution.

Key metrics: GAAP loss from operations of $5.7M for Q3 2025 and $21.5M for the nine months ended Sept 30, 2025; Adjusted loss from operations was $2.5M (Q3) and $7.8M (nine months), representing a 10% and 25% reduction versus the comparable 2024 periods. The company highlights investments in workforce, IT, and Tevogen.AI while emphasizing cost-efficient drug development.

Tevogen (Nasdaq: TVGN) announced on Nov 5, 2025 completion of T cell target identification for five additional HLA restrictions, expanding ExacTcell™ coverage beyond the initial HLA-A*02:01.

The company says the step could extend TVGN 489 access from ~25% to approximately 65% of the U.S. population. The TVGN 489 proof-of-concept trial reported 100% viral clearance, no reinfections, and no Long COVID cases in high-risk patients.

Tevogen (Nasdaq: TVGN) clarified its reported accumulated deficit and provided cash-versus-noncash context for investors on Nov 3, 2025. The company said it has raised under $42 million in total cash to June 30, 2025, while GAAP shows an accumulated deficit of $129 million. Management explained that backing out cash yields a cash loss of ~ $41 million and about $88 million of non-cash expenses, offset by $110 million in Additional Paid-in Capital and a capital raise of over $8.8 million, leaving a stockholders’ deficit of under $9.5 million.

The company plans to publish reconciled non-GAAP metrics with its Form 10-Q for Q3 2025 and reiterated forward-looking risks including the need for additional capital.

Tevogen (Nasdaq: TVGN) outlined recent progress in making allogeneic T cell therapies more accessible, citing dose-finding clinical data for TVGN 489 and demand from Long COVID patients. Management highlighted an rNPV valuation of $9–$11 billion for TVGN 489 and a projected 5-year top-line revenue of ~ $6.5 billion for a liver-cancer prevention product targeting high-risk chronic Hepatitis B. Tevogen.AI completed alpha and began beta of PredicTcell, reported large time reductions in target analysis with potential billions in development savings, and received an international patent publication (WO2025/129197). The company expanded headquarters and created a Long COVID contact channel receiving global inquiries.

Tevogen (Nasdaq: TVGN) provided an update on its investigational precision T cell therapy TVGN 489 on Oct 15, 2025, citing growing public interest from Long COVID patients and stakeholders.

The company said a dose-finding clinical trial showed a favorable safety profile and was peer-reviewed and published in Blood Advances. Tevogen plans collaborations with government programs, patient organizations, and major healthcare providers to expedite development and access when regulatory pathways permit, and has created a dedicated Long COVID contact at longCOVID@tevogen.com. The company also stated it is maximizing capital efficiency and maintains access to financing to support advancement toward commercialization.